What is the causal relationship between mitochondrial RNA transport defects and energy metabolism in ALS/FTD/AD?

While mitochondrial dysfunction was proposed as a therapeutic target, the debate did not resolve whether RNA transport defects are primary drivers or downstream consequences of neurodegeneration. This distinction is essential for therapeutic prioritization.

Source: Debate session sess_SDA-2026-04-01-gap-v2-68d9c9c1 (Analysis: SDA-2026-04-01-gap-v2-68d9c9c1)

{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:55.219550+00:00”, “resolution_summary”: “Resolved by hypothesis h-72c719461c: C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD. Supporting evidence includes debate sess_sda-2026-04-01-gap-v2-68d9c9c1.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-72c719461c”, “title”: “C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD”, “score”: 0.4, “reason”: “6 token overlaps; entity overlap: als, ftd”, “analysis_id”: “test-hypothesis-fixtures-v1”, “target_gene”: “C9orf72”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.72, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“21944792”, “28960178”, “29460270”, “39605053”, “40520109”]}, {“id”: “h-alsmnd-c5d2e9c2edeb”, “title”: “SFPQ Paralog Displacement Triggers Cryptic Polyadenylation and Global RNA Stability Loss in ALS Motor Neurons”, “score”: 0.355, “reason”: “7 token overlaps; entity overlap: als, rna”, “analysis_id”: null, “target_gene”: “SFPQ,NONO,PSP1,TARDBP,poly(A) machinery,CPSF,PABPN1”, “target_pathway”: null, “disease”: “ALS”, “composite_score”: 0.864139, “confidence_score”: 0.75, “status”: “open”, “pubmed_evidence_ids”: [“36414621”, “40369342”, “41120750”, “41836882”]}, {“id”: “h-var-a0933e666d”, “title”: “Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD”, “score”: 0.343, “reason”: “16 token overlaps; entity overlap: als, ftd”, “analysis_id”: “SDA-2026-04-01-gap-20260401-225149”, “target_gene”: “AIM2, CASP1, IL1B, PYCARD, TARDBP”, “target_pathway”: “Microglial AIM2 inflammasome activation via phagocytosed neuron-derived mtDNA in TDP-43 proteinopathy”, “disease”: “neurodegeneration”, “composite_score”: 0.8240000000000001, “confidence_score”: 0.76, “status”: “proposed”, “pubmed_evidence_ids”: [“27519954”, “28506519”, “29263430”, “29643512”, “30610225”]}, {“id”: “h-alsmnd-006d646506ab”, “title”: “hnRNP A2/B1 Staufen2-Mediated Axonal RNA Granule Transport Failure Drives Distal Axon Degeneration in ALS”, “score”: 0.339, “reason”: “6 token overlaps; entity overlap: als, rna”, “analysis_id”: null, “target_gene”: “HNRNPA2B1,STAU2,PRMT1,GSK3B,MAP1B,β-actin,axonal transport machinery”, “target_pathway”: null, “disease”: “ALS”, “composite_score”: 0.851136, “confidence_score”: 0.75, “status”: “open”, “pubmed_evidence_ids”: [“30344044”, “34290090”, “40737092”, “41044342”]}, {“id”: “h-alsmnd-9d62ae58bdc1”, “title”: “RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA Processing Condensates Toward Pathological Aggregation in ALS”, “score”: 0.322, “reason”: “5 token overlaps; entity overlap: als, rna”, “analysis_id”: null, “target_gene”: “RBM45,GSK3B,TDP-43,TARDBP,hnRNP A1,HNRNPA1,phase separation,Liquid droplet”, “target_pathway”: null, “disease”: “ALS”, “composite_score”: 0.868053, “confidence_score”: 0.75, “status”: “open”, “pubmed_evidence_ids”: [“22993125”, “25939382”, “29140459”, “32586379”, “34118419”]}], “debate_matches”: [{“id”: “sess_sda-2026-04-01-gap-v2-68d9c9c1”, “title”: “RNA binding protein dysregulation across ALS FTD and AD”, “score”: 0.595, “reason”: “3 token overlaps; entity overlap: als, ftd, rna”, “analysis_id”: “sda-2026-04-01-gap-v2-68d9c9c1”, “quality_score”: 0.88, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_sda-2026-04-01-gap-v2-68d9c9c1_20260412-080046”, “title”: “RNA binding protein dysregulation across ALS FTD and AD”, “score”: 0.595, “reason”: “3 token overlaps; entity overlap: als, ftd, rna”, “analysis_id”: “sda-2026-04-01-gap-v2-68d9c9c1”, “quality_score”: 0.72, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-20260410-172514”, “title”: “RNA binding protein dysregulation across ALS FTD AD”, “score”: 0.595, “reason”: “3 token overlaps; entity overlap: als, ftd, rna”, “analysis_id”: “SDA-2026-04-13-gap-20260410-172514”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-111130-9967ed0e”, “title”: “The debate highlighted that RNA granules serve essential physiological functions, but it’s unclear whether therapeutic dissolution would be neuroprotective or neurotoxic. This fundamental safety question must be resolved before pursuing granule-targeting therapies.\n\nSource: Debate session sess_sda-2026-04-01-gap-v2-68d9c9c1 (Analysis: sda-2026-04-01-gap-v2-68d9c9c1)”, “score”: 0.459, “reason”: “10 token overlaps; entity overlap: rna”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-111130-9967ed0e”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_hypdebate_h_72c719461c_20260427_113510”, “title”: “Hypothesis debate: C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD”, “score”: 0.413, “reason”: “3 token overlaps; entity overlap: als, ftd”, “analysis_id”: “test-hypothesis-fixtures-v1”, “quality_score”: 0.58, “status”: “completed”, “target_artifact_id”: “h-72c719461c”, “target_artifact_type”: “hypothesis”}], “paper_matches”: []}